Cart
sales@molnova.com
Z-360
CAS No. 209219-38-5
Z-360( Nastorazepide )
Catalog No. M13278 CAS No. 209219-38-5
A novel potent, orally active CCK-2/gastrin receptor antagonist with Ki of 0.47 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 117 | In Stock |
|
| 5MG | 92 | In Stock |
|
| 10MG | 180 | In Stock |
|
| 25MG | 345 | In Stock |
|
| 50MG | 514 | In Stock |
|
| 100MG | 742 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameZ-360
-
NoteResearch use only, not for human use.
-
Brief DescriptionA novel potent, orally active CCK-2/gastrin receptor antagonist with Ki of 0.47 nM.
-
DescriptionA novel potent, orally active CCK-2/gastrin receptor antagonist with Ki of 0.47 nM; significantly reduces gastrin-induced PKB/Akt phosphorylation in human CCK-2 receptor-expressing cells; significantly inhibits the growth of MiaPaCa2, also suppresses pancreatic tumor growth and prolong survival in a pancreatic carcinoma xenograft model combined with gemcitabine; prevents up-regulation of ephrin B1 gene expression and phosphorylation of NR2B via suppression of interleukin-1 β production in a cancer-induced pain model in mice.Pancreatic Cancer Phase 2 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsNastorazepide
-
PathwayGPCR/G Protein
-
TargetCholecystokinin Receptor
-
RecptorCholecystokinin Receptor
-
Research AreaCancer
-
IndicationPancreatic Cancer
Chemical Information
-
CAS Number209219-38-5
-
Formula Weight520.6199
-
Molecular FormulaC29H36N4O5
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 32 mg/mL
-
SMILESO=C(O)C1=CC=CC(NC(N[C@@H]2CN(C3CCCCC3)C4=CC=CC=C4N(CC(C(C)(C)C)=O)C2=O)=O)=C1
-
Chemical NameBenzoic acid, 3-[[[[(3R)-5-cyclohexyl-1-(3,3-dimethyl-2-oxobutyl)-2,3,4,5-tetrahydro-2-oxo-1H-1,5-benzodiazepin-3-yl]amino]carbonyl]amino]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kawasaki D, et al. Cancer Chemother Pharmacol. 2008 Apr;61(5):883-92.
2. Meyer T, et al. Eur J Cancer. 2010 Feb;46(3):526-33.
3. Orikawa Y, et al. Mol Pain. 2010 Oct 28;6:72.
molnova catalog
related products
-
JNJ-26070109
A novel, potent, selective orally active CCK-2 receptor antagonist with pKi of 8.49 for hCCK2.
-
A-65186
A-65186 is an A-type glutamatergic cholecystokinin (CCK) antagonist used to study inflammation and gastrointestinal tract injury.
-
Netazepide
Netazepide (YF476, Sograzepide)?is a potent, selective and orally active gastrin/CCK-2 antagonist with IC50 of 0.1 nM.
